Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden

Transfusion

Volumn 54, Issue 3, 2014, Pages 646-649

  Voskaridou, Ersi ^a   Komninaka, Veroniki ^b   Karavas, Antonis ^b   Terpos, Evangelos ^b   Akianidis, Vasilis ^b   Christoulas, Dimitrios ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; MONOTHERAPY; THALASSEMIA MAJOR;

ADULT; BENZOATES; BETA-THALASSEMIA; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; TRIAZOLES;

EID: 84896035687     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12335     Document Type: Article

References (13)

1. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD,. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919-1929.
2. Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D,. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev 2012;(2): CD007476.
3. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ,. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007;(3): CD004839.
4. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW,. Combined iron chelation therapy. Ann N Y Acad Sci 2010; 1202: 79-86.
5. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D,. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004; 126: 736-742.
6. Olivieri NF, Brittenham GM,. Iron chelating therapy and the treatment of thalassaemia. Blood 1997; 89: 739-761.
7. Olivieri NF,. The β-thalassemias. N Eng J Med 1999; 341: 99-109.
8. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J,. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101: 91-96.
9. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V,. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-475.
10. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ,. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
11. Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC,. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120: 123-128.
12. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C,. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol 2010; 32: 400-403.
13. Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ,. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica 2013; 98: 129-135.